HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.